Results 191 to 200 of about 910,008 (206)

SMARCB1 (INI1) Deficient Tumours of the Uterine Cervix: Report of Two Cases, Including One Associated With an NTRK Fusion.

International Journal of Gynecological Pathology
Pathogenic variants (mutations) and other molecular events involving subunits of the SWItch/Sucrose Non-Fermentable chromatin remodelling complex are common in a wide variety of malignancies.
R. Razack, Jennifer L Butt, I. Hostein, Valérie Velasco, S. Croce, Carel Olory, Lili Fu, William D. Foulkes, W. McCluggage   +8 more
semanticscholar   +1 more source

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins

Clinical Cancer Research, 2018
Abstract The oncogenesis-promoting role of chromosomal rearrangements for several hematologic and solid malignancies is well recognized. However, identifying targetable, actionable, and druggable chromosomal rearrangements remains a challenge. Targeting gene fusions and chromosomal rearrangements is an effective strategy in treating gene
Ed S, Kheder, David S, Hong
openaire   +2 more sources

NTRK fusion genes in thyroid cancer

Endocrine Abstracts, 2021
Barbora Pekova, Vlasta Sykorova, Karolina Mastnikova, Eliska Vaclavikova, Jitka Moravcova, Vlcek Petr, Petr Lastuvka, Milos Taudy, Rami Cisel, Petr Bavor, Daniela Kodetova, Martin Kodetova, Jana Drozenova, Jaromir Kodetova, Petr Hrabal, Josef Vcelak, Bela Bendlova   +16 more
openaire   +1 more source

Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.

Lung Cancer, 2023
B. Cho, Chao-Hua Chiu, E. Massarelli, G. Buchschacher, Koichi Goto, T. Overbeck, H. Loong, Cheng Ean Chee, Pilar Garrido, Xiaorong Dong, Yun Fan, Shun Lu, Sven Schwemmers, W. Bordogna, H. Zeuner, Stuart Osborne, Thomas John   +16 more
semanticscholar   +1 more source

Cost-effectiveness of NTRK testing strategies for detecting NTRK fusions in solid tumors in China.

Journal of Clinical Oncology
3131 Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in many solid tumors. With the inclusion of the targeted drug Entrectinib in China's national reimbursement drug list, the demand for NTRK testing has also increased.
Jian Wang, Lifeng Wang, Shenglei Li, Wen Chen   +3 more
openaire   +1 more source

Entrectinib bei NTRK-Fusion-positiven Tumoren

Im Focus Onkologie, 2018
openaire   +2 more sources

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2

Annals of Oncology, 2022
J. Lu, C.M. Blakely, M. Barve, C.H. Chung, S.N. Waqar, X. Hu, J-P. Delord, M.J. Krzakowski, K. Yonemori, D.T. Chen, D. Klingbiel, S. Heinzmann, C. Le Tourneau   +12 more
openaire   +1 more source

BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients

Journal of the National Comprehensive Cancer Network, 2021
Landon Z. Marshall, Andrew J. Klink, Abhishek Kavati, Ruth Antoine, Sibyl Anderson, Bruce Feinberg   +5 more
openaire   +1 more source

Refining NTRK Fusion Detection in Papillary Thyroid Carcinoma Through Pan-TRK Immunohistochemistry and Histopathologic Features

Endocrine pathology
Hyun Lee, Sue Youn Kim, Ji Min Park, Seungpil Jung, O. Mete, Chan Kwon Jung   +5 more
semanticscholar   +1 more source

NTRK gene fusions: a rough diamond ready to sparkle

The Lancet Oncology, 2020
openaire   +2 more sources